Discover proven strategies and insights refined over more than 5,000 launches around the world.
Oncology continues to be one of the growth engines of the biopharmaceutical industry. Its promise keeps attracting many players and results in overwhelming complexity and fierce competition, which disrupts the oncology business fundamentals. Therefore, a new go-to-market approach is needed.
This white paper explores the future of oncology commercialisation, including new realities oncology innovators are facing, the four pillars of the future oncology go-to-market model and illustrative examples of innovative practices that we are observing
Key strategic considerations for pricing and market access
Accelerate and support your organization's RWE capabilities
Gain access to complete electronic medical record (EMR) data on more than 2M oncology patients from community hospital systems
Artificial Intelligence combines meaningful data and smart analytics to measure and optimize omnichannel customer engagement
Discover proven strategies and insights refined over more than 5,000 launches around the world.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.